Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Adalimumab - AbbVie/MedImmune

Drug Profile

Adalimumab - AbbVie/MedImmune

Alternative Names: ABT-D2E7; D2E7; Humira; LU 200134; Raheara

Latest Information Update: 06 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cambridge Antibody Technology
  • Developer AbbVie; Eisai Co Ltd; Interstitial Cystitis Study
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antineoplastics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Skin disorder therapies
  • Mechanism of Action Immunosuppressants; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Uveitis; Hidradenitis suppurativa
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ankylosing spondylitis; Behcet's syndrome; Crohn's disease; Hidradenitis suppurativa; Juvenile rheumatoid arthritis; Plaque psoriasis; Psoriatic arthritis; Pustular psoriasis; Rheumatoid arthritis; Spondylarthritis; Ulcerative colitis; Uveitis
  • Phase III Pyoderma
  • Discontinued Interstitial cystitis

Most Recent Events

  • 11 Nov 2019 AbbVie completes a phase III trial for Ulcerative Colitis in Germany, Hungary, Belgium, Netherlands, Spain, Poland, Czech Republic, Denmark, Austria, France, Israel, Romania, Switzerland, Ukraine, United Kingdom, USA, Canada, Japan and Slovakia (NCT02065622)
  • 30 May 2019 AbbVie completes a phase III trial in Hidradenitis suppurativa in Japan (SC) (NCT02904902)
  • 14 May 2019 Boehringer Ingelheim enters into patent licensing agreement with AbbVie for adalimumab patents
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top